JP2009538853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538853A5 JP2009538853A5 JP2009512482A JP2009512482A JP2009538853A5 JP 2009538853 A5 JP2009538853 A5 JP 2009538853A5 JP 2009512482 A JP2009512482 A JP 2009512482A JP 2009512482 A JP2009512482 A JP 2009512482A JP 2009538853 A5 JP2009538853 A5 JP 2009538853A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrido
- imidazo
- pyrazine
- methoxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 35
- 208000035475 disorder Diseases 0.000 claims 34
- -1 4-isopropyloxy-8-methoxy-3-methyl-1-propyl-imidazo [1,5-a] pyrido [3,2-e] pyrazine 8-methoxy-1,3-dimethyl-4- (2,3,6-trifluorobenzyloxy) -imidazo [1,5-a] pyrido [3,2-e] pyrazine Chemical compound 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000004122 cyclic group Chemical group 0.000 claims 17
- 208000028017 Psychotic disease Diseases 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical group 0.000 claims 14
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 12
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 10
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 230000003542 behavioural effect Effects 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 206010026749 Mania Diseases 0.000 claims 6
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000008451 emotion Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000036651 mood Effects 0.000 claims 4
- 230000002085 persistent effect Effects 0.000 claims 4
- 208000022821 personality disease Diseases 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000012239 Developmental disease Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 208000013403 hyperactivity Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 230000001107 psychogenic effect Effects 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021030 Hypomania Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 2
- 150000008065 acid anhydrides Chemical class 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000036630 mental development Effects 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- MHLWHSGDDQJVTO-UHFFFAOYSA-N 1-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)-3-propan-2-ylurea Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2NC(=O)NC(C)C MHLWHSGDDQJVTO-UHFFFAOYSA-N 0.000 claims 1
- SKKJBUVASPYLCP-UHFFFAOYSA-N 10-cyclopentyloxy-13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 13-ethyl-4-methoxy-11-methyl-10-propoxy-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N1=CC2=CN(OC)CN2C2=C1C(OCCC)=C(C)CN2CC.N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OC1CCCC1 SKKJBUVASPYLCP-UHFFFAOYSA-N 0.000 claims 1
- XNISOERFESPZHR-UHFFFAOYSA-N 10-ethyl-4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-10,11-dimethyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2C.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2CC XNISOERFESPZHR-UHFFFAOYSA-N 0.000 claims 1
- XEQRRFBPNRKREH-UHFFFAOYSA-N 12-methoxy-10,11-dimethyl-4-(4-methyl-2-propylimidazol-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CCCN1C(OC)C(C)=C(C)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CCC XEQRRFBPNRKREH-UHFFFAOYSA-N 0.000 claims 1
- HDEZRZBDCNJDLJ-UHFFFAOYSA-N 12-methoxy-10,11-dimethyl-4-(4-methylpiperazin-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CCCN1C(OC)C(C)=C(C)C(N=CC2=C3)=C1N2CN3N1CCN(C)CC1 HDEZRZBDCNJDLJ-UHFFFAOYSA-N 0.000 claims 1
- VODYAHMSBGDIQH-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-10-methylsulfanyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-11-methyl-10-methylsulfanyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2SC.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2SC VODYAHMSBGDIQH-UHFFFAOYSA-N 0.000 claims 1
- PGDQQHOVGFSIGS-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-10-methylsulfinyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-11-methyl-10-methylsulfonyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2S(C)=O.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2S(C)(=O)=O PGDQQHOVGFSIGS-UHFFFAOYSA-N 0.000 claims 1
- ZFESMIUEBMKAHN-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound C(C)N1CC(=CC=2N=CC=3N(C21)CN(C3)OC)C.CON3CN2C(C=NC1=C2N(CC(=C1)C)CCC)=C3 ZFESMIUEBMKAHN-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims 1
- CNDQETATHMBYDH-UHFFFAOYSA-N 4-(2-ethyl-4-methylimidazol-1-yl)-12-methoxy-10,11-dimethyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CCCN1C(OC)C(C)=C(C)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CC CNDQETATHMBYDH-UHFFFAOYSA-N 0.000 claims 1
- HBUHADWINCSDBW-UHFFFAOYSA-N 4-methoxy-10,11,13-trimethyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CN1CC(C)=C(C)C2=C1N1CN(OC)C=C1C=N2 HBUHADWINCSDBW-UHFFFAOYSA-N 0.000 claims 1
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 claims 1
- 206010054196 Affect lability Diseases 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006362 Brief psychotic disorder, with postpartum onset Diseases 0.000 claims 1
- CUNOIBNJEWZQLY-UHFFFAOYSA-N C(C)N1CC(=C(C=2N=CC=3N(C21)CN(C3)OC)OC(C)C)C.COC3=C(C=NC2=C3N=CC=3N2CN(C3)OC)C Chemical compound C(C)N1CC(=C(C=2N=CC=3N(C21)CN(C3)OC)OC(C)C)C.COC3=C(C=NC2=C3N=CC=3N2CN(C3)OC)C CUNOIBNJEWZQLY-UHFFFAOYSA-N 0.000 claims 1
- SUUZQBPJXAPCMG-UHFFFAOYSA-N C(C)OC(=O)[Mg]C(F)F Chemical compound C(C)OC(=O)[Mg]C(F)F SUUZQBPJXAPCMG-UHFFFAOYSA-N 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- XZYWJSFVJBKGTK-UHFFFAOYSA-N COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)C)C.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C Chemical compound COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)C)C.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C XZYWJSFVJBKGTK-UHFFFAOYSA-N 0.000 claims 1
- UOJDUUNYGYQDEO-UHFFFAOYSA-N COC1=CCN(C2=C1N=CC=1N2CN(C1)OC)CCC.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C Chemical compound COC1=CCN(C2=C1N=CC=1N2CN(C1)OC)CCC.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C UOJDUUNYGYQDEO-UHFFFAOYSA-N 0.000 claims 1
- XJCQRSXQWMNSPO-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)N)C)CCC)=C1.CON1CN3C(C=NC2=C3N(CC(=C2NC(=O)NC)C)CCC)=C1 Chemical compound CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)N)C)CCC)=C1.CON1CN3C(C=NC2=C3N(CC(=C2NC(=O)NC)C)CCC)=C1 XJCQRSXQWMNSPO-UHFFFAOYSA-N 0.000 claims 1
- KINZNAKMKMXZSU-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)OC)C)CCC)=C1.N1=CC=NC3=C1C=CC=N3 Chemical compound CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)OC)C)CCC)=C1.N1=CC=NC3=C1C=CC=N3 KINZNAKMKMXZSU-UHFFFAOYSA-N 0.000 claims 1
- GJNBAHWMXFEVEJ-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N=CC(=C3SC)C)=C1.CN1CC(=C(C=3N=CC=2N(C31)CN(C2)OC)SC)C Chemical compound CON1CN2C(C=NC3=C2N=CC(=C3SC)C)=C1.CN1CC(=C(C=3N=CC=2N(C31)CN(C2)OC)SC)C GJNBAHWMXFEVEJ-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012559 Developmental delay Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000034347 Faecal incontinence Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001836 Firesetting Behavior Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 239000007818 Grignard reagent Substances 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- VYQHVJLYCVBMPP-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-phenyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)methanesulfonamide Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)NS(C)(=O)=O)=C2N1C1=CC=CC=C1 VYQHVJLYCVBMPP-UHFFFAOYSA-N 0.000 claims 1
- SPQOJNXJTIXEIH-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)-4-methylbenzenesulfonamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2NS(=O)(=O)C1=CC=C(C)C=C1 SPQOJNXJTIXEIH-UHFFFAOYSA-N 0.000 claims 1
- PYLLDDLPBABELC-UHFFFAOYSA-N N-[11-methyl-4-(4-methyl-2-propylimidazol-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl]methanesulfonamide Chemical compound CCCN1CC(C)=C(NS(C)(=O)=O)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CCC PYLLDDLPBABELC-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 101710122057 Phospholemman-like protein Proteins 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010039987 Senile psychosis Diseases 0.000 claims 1
- 206010040030 Sensory loss Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010042008 Stereotypy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- PAJXSBMFHFVGLO-UHFFFAOYSA-N chembl1083458 Chemical compound C1=C(OC)N=C2N3C(CCC)=NC(C)=C3C(NC(=O)OCC)=NC2=C1 PAJXSBMFHFVGLO-UHFFFAOYSA-N 0.000 claims 1
- GQYPTVVKCVYXLX-UHFFFAOYSA-N chembl1086265 Chemical compound C1=C(OC)N=C2N3C(CCC)=NC(C)=C3C(C#N)=NC2=C1 GQYPTVVKCVYXLX-UHFFFAOYSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- 210000000078 claw Anatomy 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 150000004795 grignard reagents Chemical class 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000012198 paraphilic disease Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000021011 postpartum psychosis Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229940124811 psychiatric drug Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000002899 segmental dystonia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000013623 stereotypic movement disease Diseases 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80924206P | 2006-05-30 | 2006-05-30 | |
| PCT/EP2007/004748 WO2007137820A1 (en) | 2006-05-30 | 2007-05-29 | PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538853A JP2009538853A (ja) | 2009-11-12 |
| JP2009538853A5 true JP2009538853A5 (enExample) | 2010-07-22 |
Family
ID=38441604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512482A Pending JP2009538853A (ja) | 2006-05-30 | 2007-05-29 | ピリド［３，２−ｅ］ピラジン、該化合物のホスホジエステラーゼ１０の阻害剤としての使用、及び該化合物の製造方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7550465B2 (enExample) |
| EP (1) | EP2021342A1 (enExample) |
| JP (1) | JP2009538853A (enExample) |
| KR (1) | KR20090013834A (enExample) |
| CN (1) | CN101454324A (enExample) |
| AR (1) | AR061206A1 (enExample) |
| AU (1) | AU2007267392A1 (enExample) |
| BR (1) | BRPI0712132A2 (enExample) |
| CA (1) | CA2651849A1 (enExample) |
| CL (1) | CL2007001554A1 (enExample) |
| CR (1) | CR10358A (enExample) |
| GT (1) | GT200800265A (enExample) |
| IL (1) | IL193740A0 (enExample) |
| MX (1) | MX2008014569A (enExample) |
| NO (1) | NO20085326L (enExample) |
| PE (1) | PE20080711A1 (enExample) |
| RU (1) | RU2008152440A (enExample) |
| SV (1) | SV2009003048A (enExample) |
| TW (1) | TW200817400A (enExample) |
| WO (1) | WO2007137820A1 (enExample) |
| ZA (1) | ZA200807517B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2008072779A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| EP2225248A1 (en) * | 2007-11-30 | 2010-09-08 | Wyeth LLC | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| MX2010012037A (es) * | 2008-05-07 | 2010-11-30 | Lundbeck & Co As H | Composiciones y uso utiles para tratar trastornos cognitivos. |
| WO2010054253A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| WO2012012542A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals, Inc. | Methods of use of cyclic amide derivatives to treat schizophrenia |
| RU2746871C2 (ru) * | 2010-07-20 | 2021-04-21 | Сиренейк Фармасьютикалз Инк. | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| BR112014011173A2 (pt) | 2011-11-09 | 2017-05-09 | Abbvie Deutschland | carboxamidas heterocíclicas úteis como inibidores de fosfodiesterase tipo 10a |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| EA029892B1 (ru) | 2012-04-25 | 2018-05-31 | Такеда Фармасьютикал Компани Лимитед | Азотсодержащее гетероциклическое соединение |
| JP6205356B2 (ja) * | 2012-07-13 | 2017-09-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| HK1206728A1 (en) | 2012-09-17 | 2016-01-15 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| MX2015012008A (es) | 2013-03-14 | 2016-04-15 | Abbvie Deutschland | Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a. |
| EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
| EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC CONNECTION |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| CN114702495A (zh) | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| JP2020525436A (ja) | 2017-06-21 | 2020-08-27 | ミネルバ・ニューロサイエンシズ・インコーポレイテッド | 胃耐性制御放出経口剤形 |
| WO2020065583A1 (en) | 2018-09-28 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| CN114524808B (zh) * | 2022-02-21 | 2023-10-24 | 深圳市儿童医院 | 一种吡唑衍生物及其作为pde10抑制剂的用途 |
| CN114524806B (zh) * | 2022-02-22 | 2024-09-03 | 深圳市儿童医院 | 一种三氮唑衍生物及其作为pde10抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| EP0590022A1 (en) * | 1991-06-14 | 1994-04-06 | PHARMACIA & UPJOHN COMPANY | IMIDAZO 1,5-a]QUINOXALINES |
| DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
-
2007
- 2007-05-18 TW TW096117906A patent/TW200817400A/zh unknown
- 2007-05-24 US US11/753,207 patent/US7550465B2/en not_active Expired - Fee Related
- 2007-05-29 AU AU2007267392A patent/AU2007267392A1/en not_active Abandoned
- 2007-05-29 CA CA002651849A patent/CA2651849A1/en not_active Abandoned
- 2007-05-29 WO PCT/EP2007/004748 patent/WO2007137820A1/en not_active Ceased
- 2007-05-29 EP EP07725639A patent/EP2021342A1/en not_active Withdrawn
- 2007-05-29 MX MX2008014569A patent/MX2008014569A/es active IP Right Grant
- 2007-05-29 RU RU2008152440/04A patent/RU2008152440A/ru not_active Application Discontinuation
- 2007-05-29 CN CNA2007800193040A patent/CN101454324A/zh active Pending
- 2007-05-29 AR ARP070102310A patent/AR061206A1/es unknown
- 2007-05-29 KR KR1020087031860A patent/KR20090013834A/ko not_active Withdrawn
- 2007-05-29 JP JP2009512482A patent/JP2009538853A/ja active Pending
- 2007-05-29 BR BRPI0712132-6A patent/BRPI0712132A2/pt not_active IP Right Cessation
- 2007-05-30 PE PE2007000674A patent/PE20080711A1/es not_active Application Discontinuation
- 2007-05-30 CL CL2007001554A patent/CL2007001554A1/es unknown
-
2008
- 2008-08-28 IL IL193740A patent/IL193740A0/en unknown
- 2008-08-29 ZA ZA200807517A patent/ZA200807517B/xx unknown
- 2008-10-02 SV SV2008003048A patent/SV2009003048A/es active IP Right Grant
- 2008-10-10 CR CR10358A patent/CR10358A/es not_active Application Discontinuation
- 2008-11-27 GT GT200800265A patent/GT200800265A/es unknown
- 2008-12-19 NO NO20085326A patent/NO20085326L/no not_active Application Discontinuation
-
2009
- 2009-05-19 US US12/454,537 patent/US20090239874A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008152440A (ru) | ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| RU2744988C2 (ru) | Соединения и композиции для подавления активности shp2 | |
| JP2009538852A5 (enExample) | ||
| JP7114604B2 (ja) | 脆弱ｘ症候群の治療のためのプリドピジンの使用 | |
| JP5646126B2 (ja) | 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法 | |
| JP7321097B2 (ja) | 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法 | |
| RU2010126622A (ru) | Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10 | |
| JP6932641B2 (ja) | 異常不随意運動障害の処置のための方法 | |
| US20180200256A1 (en) | Novel methods | |
| JP7282082B2 (ja) | 置換ピリミジンピペラジン化合物及びその使用 | |
| EP4674482A2 (en) | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof | |
| JP2021519267A5 (enExample) | ||
| JP2022515766A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| US6075028A (en) | Method of treating Tourette's syndrome and related CNS disorders | |
| CN115175911A (zh) | 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法 | |
| US20180244623A1 (en) | N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto | |
| JPH11510143A (ja) | 注意不足／活動亢進障害の処置 | |
| CN101778628B (zh) | 治疗焦虑的方法 | |
| EP4583862A1 (en) | Use of mdma for treatment of stress-related disorders | |
| JPH08500326A (ja) | 免疫抑制剤としてのスピペロンまたはスピペロン誘導体の使用 | |
| KR20230136142A (ko) | 치료 방법 | |
| CN102026639A (zh) | 用于治疗注意力缺陷障碍和性功能障碍的3-羟基吉哌隆 | |
| JP2018534287A5 (enExample) | ||
| WO2022217247A1 (en) | Isochroman derivatives and compositions and uses thereof |